Sie suchten nach: addition of regulations ( germany , england ) (Dänisch - Finnisch)

harmonisation of requirements for equine influenza vaccines specific requirements for substitution or addition of a strain
harmonisation of requirements for equine influenza vaccines specific requirements for substitution or addition of a strain

på engelsk butter for the addition of tracers for use in accordance with article 6(1)(a) of regulation (ec) no 1898/2005
englanniksi butter for the addition of tracers for use in accordance with article 6(1)(a) of regulation (ec) no 1898/2005

på engelsk butter for concentration and the addition of tracers for use in accordance with article 6(1)(a) of regulation (ec) no 1898/2005
englanniksi butter for concentration and the addition of tracers for use in accordance with article 6(1)(a) of regulation (ec) no 1898/2005

på engelsk article 4 of regulation (ec) no 2058/96
englanniksi article 4 of regulation (ec) no 2058/96

engelsk licence for additional quantity, article 6 of regulation (ec) no 2081/2005,
englanniksi licence for additional quantity, article 6 of regulation (ec) no 2081/2005,

på engelsk limitation provided for in article 1(2) of regulation (ec) no 1018/2005
englanniksi limitation provided for in article 1(2) of regulation (ec) no 1018/2005

på engelsk for export without refund under article 6 of regulation (ec) no 1868/94
englanniksi for export without refund under article 6 of regulation (ec) no 1868/94

engelsk products intended for processing and for the final destination referred to in article 3(b) and (c) of regulation (ec) no 1573/2005
englanniksi products intended for processing and for the final destination referred to in article 3(b) and (c) of regulation (ec) no 1573/2005

på engelsk to be released for consumption in réunion — article 11a of regulation (eec) no 1418/76
englanniksi to be released for consumption in réunion — article 11a of regulation (eec) no 1418/76

core summary of product characteristics for hepatitis b immunoglobulin revision of core summary of product characteristics for human normal immunoglobulin for intravenous use – addition of indication for treatment of parvovirus b19 infection revision of core summary of product characteristics for human plasma derived factor vii products and human plasma prothrombin complex revision of core summary of product characteristics for factor viii inhibitor bypassing fraction warning on transmissible agents for patient leaflets and summary of product characteristics revision of core summary of product characteristics for human anti- d immunoglobulin for intravenous and/ or intramuscular use (cpmp/ bpwg/ 574/ 99)
core summary of product characteristics for hepatitis b immunoglobulin revision of core summary of product characteristics for human normal immunoglobulin for intravenous use – addition of indication for treatment of parvovirus b19 infection revision of core summary of product characteristics for human plasma derived factor vii products and human plasma prothrombin complex revision of core summary of product characteristics for factor viii inhibitor bypassing fraction warning on transmissible agents for patient leaflets and summary of product characteristics revision of core summary of product characteristics for human anti- d immunoglobulin for intravenous and/ or intramuscular